Revolution Medicines Reports Progress Across Pipeline of Targeted Therapeutics for RAS-Addicted Cancers in Presentation at 40th Annual J.P. Morgan Healthcare Conference

NEXT STORY
Enterin and Their Collaborators at NIH Announce That Alpha-Synuclein, the Culprit in Parkinson’s Disease, is Core and Central to Normal Immune Function
PREV STORY
Next Generation Sequencing (NGS) Market Registered at CAGR 17.1% New Business Opportunities, Growth Rate, Development Trend and Feasibility Studies by 2029
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Phase III data in The Lancet show Novartis siponimod significantly improves outcomes in patients with secondary progressive MS

EXPAND shows oral siponimod (BAF312) is the first potential therapy to meaningfully delay disability ...

author_avatar
NASDAQ Market News

NexImmune to Explore the Use of AIM™ Direct Injection Technology in Type 1 Diabetes

author_avatar
NASDAQ Market News

Spero Therapeutics Announces Collaboration with Bill & Melinda Gates Medical Research Institute to Develop SPR720 for Tuberculosis

author_avatar
NASDAQ Market News